Rani Therapeutics Holdings Inc Cl A (RANI)

$1.28 -0.01 (-0.78%)
Market Cap 156.75M
Revenue (ttm) 1.03M
Net Income (ttm) -30.02M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -2,914.56%
Debt to Equity Ratio -1.88
Volume 396,900
Avg Vol 1,493,482
Day's Range N/A - N/A
Shares Out 121.51M
Stochastic %K 49%
Beta 0.41
Analysts Strong Sell
Price Target $9.25

Company Profile

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes...

Industry: Biotechnology
Sector: Healthcare
Phone: 408 457 3700
Address:
2051 Ringwood Avenue, San Jose, United States
Giambu
Giambu Feb. 21 at 12:21 PM
$RANI l'acquisto di azioni è una notizia vecchia
1 · Reply
wavw
wavw Feb. 20 at 6:25 PM
$RANI someone dumped heavily…
1 · Reply
DragonAlgo
DragonAlgo Feb. 20 at 1:06 PM
🐉 $RANI CALL — DragonAlgo® Signal Contract: RANI CALL Expiry: 2026-02-20 | Strike: $1.50 | Type: CALL Option Plan (premium): Entry: $0.05 Stop: $0.04 TP1: $0.07 TP2: $0.09 TP3: $0.12 Rules-based execution profile. 🔗 https://dragonalgo.com
0 · Reply
Makingmillions192
Makingmillions192 Feb. 19 at 10:26 PM
$LEXX Rani ran from a $22M mkt cap to $350M in 3 days following the oral delivery partnership. I think the same setup is possible here. Maybe bigger… DHT is a billion dollar technology in the making. $RANI
0 · Reply
APRadek
APRadek Feb. 19 at 3:38 PM
$RANI If I were a short seller, I would have closed my position long ago. One of the new directors comes from Samsara Bio Capital, which recently bought 8 million shares. This is essentially insider trading. Oh boy it will fly
2 · Reply
wavw
wavw Feb. 19 at 3:12 PM
$RANI shorts will take advantage until the management announces next steps. From 13.6 million short interest, slightly reduced to 12.9 million . Slowly covering their positions.
0 · Reply
Makingmillions192
Makingmillions192 Feb. 18 at 2:50 PM
$LEXX If they do this right we can get a $RANI type of deal and move. $10M upfront payment, with royalty payments etc. 1bn total package. Any pharma company could benefit from this technology. Hopefully we wake up to some VERY good news soon.
1 · Reply
ScalpChaser
ScalpChaser Feb. 18 at 10:04 AM
$RANI Drug delivery biotech where platform validation is the unlock.
0 · Reply
ObsidianTrend
ObsidianTrend Feb. 18 at 8:17 AM
$RANI Rani Therapeutics develops oral biologic delivery technology, facing groundbreaking but unproven technology with long development pathway [citation:historical].
0 · Reply
BBTAAPL
BBTAAPL Feb. 17 at 4:32 PM
$RANI is this thing ever going to move?
0 · Reply
Latest News on RANI
Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer

Jan 28, 2026, 7:00 AM EST - 26 days ago

Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer

Rani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill® for the Treatment of Obesity in Collaboration with ProGen

Jan 8, 2026, 7:00 AM EST - 6 weeks ago

Rani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill® for the Treatment of Obesity in Collaboration with ProGen

Rani Therapeutics to Participate in the Evercore Healthcare Conference

Nov 24, 2025, 4:05 PM EST - 3 months ago

Rani Therapeutics to Participate in the Evercore Healthcare Conference

Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update

Nov 6, 2025, 4:30 PM EST - 3 months ago

Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update

Rani Therapeutics to Present Preclinical Data on Oral Delivery of Semaglutide via the RaniPill® Capsule at ObesityWeek® 2025

Oct 30, 2025, 8:00 AM EDT - 4 months ago

Rani Therapeutics to Present Preclinical Data on Oral Delivery of Semaglutide via the RaniPill® Capsule at ObesityWeek® 2025

Rani Therapeutics Announces the Appointments of Abe Bassan and Vasudev Bailey, Ph.D. to Board of Directors

Oct 23, 2025, 4:05 PM EDT - 4 months ago

Rani Therapeutics Announces the Appointments of Abe Bassan and Vasudev Bailey, Ph.D. to Board of Directors

Rani Therapeutics Announces Closing of Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules

Oct 23, 2025, 4:01 PM EDT - 4 months ago

Rani Therapeutics Announces Closing of Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules

Rani Therapeutics: Initiating At Buy On Promising RaniPill Advancement With Chugai

Oct 20, 2025, 2:20 PM EDT - 4 months ago

Rani Therapeutics: Initiating At Buy On Promising RaniPill Advancement With Chugai

CRMD, RANI, CELC, RAPT: four biotech stocks flying high today and why

Oct 20, 2025, 9:42 AM EDT - 4 months ago

CRMD, RANI, CELC, RAPT: four biotech stocks flying high today and why

CELC CRMD RAPT

Rani Therapeutics signs up to $1.09 billion licensing deal with Japan's Chugai Pharma

Oct 17, 2025, 7:48 AM EDT - 4 months ago

Rani Therapeutics signs up to $1.09 billion licensing deal with Japan's Chugai Pharma

Rani Therapeutics Announces Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules

Oct 17, 2025, 7:31 AM EDT - 4 months ago

Rani Therapeutics Announces Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules

Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 Million Financing

Oct 17, 2025, 7:30 AM EDT - 4 months ago

Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 Million Financing

Rani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate Update

Aug 7, 2025, 4:05 PM EDT - 7 months ago

Rani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate Update

Rani Therapeutics Holdings, Inc. Announces Pricing of $3.0 Million Registered Direct Offering

Jul 15, 2025, 9:00 AM EDT - 7 months ago

Rani Therapeutics Holdings, Inc. Announces Pricing of $3.0 Million Registered Direct Offering

Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery

Jul 14, 2025, 5:00 AM EDT - 8 months ago

Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery

Rani Therapeutics Announces Research Agreement with Chugai

May 19, 2025, 8:00 AM EDT - 10 months ago

Rani Therapeutics Announces Research Agreement with Chugai

Rani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate Update

May 13, 2025, 4:05 PM EDT - 10 months ago

Rani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate Update

Rani Therapeutics Holdings, Inc. (RANI) Q4 2024 Earnings Call Transcript

Mar 31, 2025, 7:15 PM EDT - 11 months ago

Rani Therapeutics Holdings, Inc. (RANI) Q4 2024 Earnings Call Transcript

Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update

Mar 31, 2025, 4:05 PM EDT - 11 months ago

Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update

Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102

Mar 26, 2025, 4:05 PM EDT - 11 months ago

Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102

Rani Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

Mar 25, 2025, 6:00 PM EDT - 11 months ago

Rani Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering and Cancellation of Certain Existing Warrants

Oct 15, 2024, 8:30 AM EDT - 1 year ago

Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering and Cancellation of Certain Existing Warrants

Rani Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit

Oct 8, 2024, 4:05 PM EDT - 1 year ago

Rani Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit

Rani Therapeutics to Participate in September Investor Conferences

Sep 3, 2024, 4:05 PM EDT - 1 year ago

Rani Therapeutics to Participate in September Investor Conferences

Rani Therapeutics Reports Second Quarter 2024 Financial Results; Provides Corporate Update

Aug 6, 2024, 4:05 PM EDT - 1 year ago

Rani Therapeutics Reports Second Quarter 2024 Financial Results; Provides Corporate Update

Rani Therapeutics to Participate in August Investor Conferences

Jul 29, 2024, 4:05 PM EDT - 1 year ago

Rani Therapeutics to Participate in August Investor Conferences

Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering

Jul 22, 2024, 8:30 AM EDT - 1 year ago

Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering

Rani Therapeutics Announces Partnership with ProGen on Development of Oral Obesity Treatment

Jun 24, 2024, 7:00 AM EDT - 1 year ago

Rani Therapeutics Announces Partnership with ProGen on Development of Oral Obesity Treatment

Rani Therapeutics to Participate in May Investor Conferences

May 14, 2024, 8:00 AM EDT - 1 year ago

Rani Therapeutics to Participate in May Investor Conferences

Rani Therapeutics to Present Clinical and Preclinical Data on Oral Delivery of an Ustekinumab Biosimilar via the RaniPill® Capsule at Digestive Disease Week 2024

May 9, 2024, 8:00 AM EDT - 1 year ago

Rani Therapeutics to Present Clinical and Preclinical Data on Oral Delivery of an Ustekinumab Biosimilar via the RaniPill® Capsule at Digestive Disease Week 2024

Rani Therapeutics Reports First Quarter 2024 Financial Results; Provides Corporate Update

May 6, 2024, 4:05 PM EDT - 1 year ago

Rani Therapeutics Reports First Quarter 2024 Financial Results; Provides Corporate Update

Rani Therapeutics Holdings, Inc. (RANI) Q4 2023 Earnings Call Transcript

Mar 20, 2024, 7:05 PM EDT - 2 years ago

Rani Therapeutics Holdings, Inc. (RANI) Q4 2023 Earnings Call Transcript

Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update

Mar 20, 2024, 4:05 PM EDT - 2 years ago

Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update

Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results

Mar 15, 2024, 4:05 PM EDT - 2 years ago

Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results

Rani Therapeutics Announces Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin Triagonist

Dec 14, 2023, 8:00 AM EST - 2 years ago

Rani Therapeutics Announces Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin Triagonist

Rani Therapeutics Reports Third Quarter 2023 Financial Results; Provides Corporate Update

Nov 8, 2023, 4:05 PM EST - 2 years ago

Rani Therapeutics Reports Third Quarter 2023 Financial Results; Provides Corporate Update

Rani Therapeutics Announces Successful Oral Delivery of Monoclonal Antibody via High-Capacity Pill in Preclinical Study

Oct 19, 2023, 4:05 PM EDT - 2 years ago

Rani Therapeutics Announces Successful Oral Delivery of Monoclonal Antibody via High-Capacity Pill in Preclinical Study

Rani Therapeutics to Present Abstract on RT-102 at the 2023 Annual Meeting of the American Society for Bone and Mineral Research

Oct 12, 2023, 4:05 PM EDT - 2 years ago

Rani Therapeutics to Present Abstract on RT-102 at the 2023 Annual Meeting of the American Society for Bone and Mineral Research

Rani Therapeutics: Excellent Technology But Major Risks Ahead

Sep 19, 2023, 6:36 AM EDT - 2 years ago

Rani Therapeutics: Excellent Technology But Major Risks Ahead

Rani Therapeutics Initiates Phase 1 Study of RT-111 (RaniPill® Containing Ustekinumab Biosimilar, CT-P43)

Sep 18, 2023, 8:00 AM EDT - 2 years ago

Rani Therapeutics Initiates Phase 1 Study of RT-111 (RaniPill® Containing Ustekinumab Biosimilar, CT-P43)

Rani Therapeutics Announces Successful Drug Delivery of High-Capacity Pill in Preclinical Studies

Sep 7, 2023, 4:05 PM EDT - 2 years ago

Rani Therapeutics Announces Successful Drug Delivery of High-Capacity Pill in Preclinical Studies

Rani Therapeutics Reports Second Quarter 2023 Financial Results; Provides Corporate Update

Aug 11, 2023, 4:05 PM EDT - 2 years ago

Rani Therapeutics Reports Second Quarter 2023 Financial Results; Provides Corporate Update

Rani Therapeutics' Presentation On Oral Delivery of PTH for Osteoporosis Named Presidential Poster Competition Winner at ENDO 2023 Annual Conference

Jun 21, 2023, 8:00 AM EDT - 2 years ago

Rani Therapeutics' Presentation On Oral Delivery of PTH for Osteoporosis Named Presidential Poster Competition Winner at ENDO 2023 Annual Conference

Rani Therapeutics Announces Acceptance of Late-Breaking Abstract of Oral Delivery of GLP-1 Agonist at the American Diabetes Association Annual Conference

Jun 8, 2023, 8:00 AM EDT - 2 years ago

Rani Therapeutics Announces Acceptance of Late-Breaking Abstract of Oral Delivery of GLP-1 Agonist at the American Diabetes Association Annual Conference

Rani Therapeutics and Celltrion Expand Partnership to Include Adalimumab Biosimilar for RT-105

Jun 5, 2023, 8:00 AM EDT - 2 years ago

Rani Therapeutics and Celltrion Expand Partnership to Include Adalimumab Biosimilar for RT-105

Rani Therapeutics to Present at the Jefferies Healthcare Conference

Jun 1, 2023, 8:00 AM EDT - 2 years ago

Rani Therapeutics to Present at the Jefferies Healthcare Conference

Rani Therapeutics Announces Acceptance of Three Abstracts for Presentation at ENDO 2023 Annual Conference

May 31, 2023, 8:00 AM EDT - 2 years ago

Rani Therapeutics Announces Acceptance of Three Abstracts for Presentation at ENDO 2023 Annual Conference

Rani Therapeutics Appoints Kate McKinley as Chief Business Officer

May 24, 2023, 8:00 AM EDT - 2 years ago

Rani Therapeutics Appoints Kate McKinley as Chief Business Officer

Rani Therapeutics Reports First Quarter 2023 Financial Results; Provides Corporate Update

May 10, 2023, 4:05 PM EDT - 3 years ago

Rani Therapeutics Reports First Quarter 2023 Financial Results; Provides Corporate Update

Giambu
Giambu Feb. 21 at 12:21 PM
$RANI l'acquisto di azioni è una notizia vecchia
1 · Reply
wavw
wavw Feb. 20 at 6:25 PM
$RANI someone dumped heavily…
1 · Reply
DragonAlgo
DragonAlgo Feb. 20 at 1:06 PM
🐉 $RANI CALL — DragonAlgo® Signal Contract: RANI CALL Expiry: 2026-02-20 | Strike: $1.50 | Type: CALL Option Plan (premium): Entry: $0.05 Stop: $0.04 TP1: $0.07 TP2: $0.09 TP3: $0.12 Rules-based execution profile. 🔗 https://dragonalgo.com
0 · Reply
Makingmillions192
Makingmillions192 Feb. 19 at 10:26 PM
$LEXX Rani ran from a $22M mkt cap to $350M in 3 days following the oral delivery partnership. I think the same setup is possible here. Maybe bigger… DHT is a billion dollar technology in the making. $RANI
0 · Reply
APRadek
APRadek Feb. 19 at 3:38 PM
$RANI If I were a short seller, I would have closed my position long ago. One of the new directors comes from Samsara Bio Capital, which recently bought 8 million shares. This is essentially insider trading. Oh boy it will fly
2 · Reply
wavw
wavw Feb. 19 at 3:12 PM
$RANI shorts will take advantage until the management announces next steps. From 13.6 million short interest, slightly reduced to 12.9 million . Slowly covering their positions.
0 · Reply
Makingmillions192
Makingmillions192 Feb. 18 at 2:50 PM
$LEXX If they do this right we can get a $RANI type of deal and move. $10M upfront payment, with royalty payments etc. 1bn total package. Any pharma company could benefit from this technology. Hopefully we wake up to some VERY good news soon.
1 · Reply
ScalpChaser
ScalpChaser Feb. 18 at 10:04 AM
$RANI Drug delivery biotech where platform validation is the unlock.
0 · Reply
ObsidianTrend
ObsidianTrend Feb. 18 at 8:17 AM
$RANI Rani Therapeutics develops oral biologic delivery technology, facing groundbreaking but unproven technology with long development pathway [citation:historical].
0 · Reply
BBTAAPL
BBTAAPL Feb. 17 at 4:32 PM
$RANI is this thing ever going to move?
0 · Reply
Makingmillions192
Makingmillions192 Feb. 17 at 2:27 PM
$LEXX Best case scenario is we have a $RANI type move on the back of a glp1 partnership here. $8-10
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 17 at 4:14 AM
$RANI RSI: 39.71, MACD: -0.0439 Vol: 0.08, MA20: 1.29, MA50: 1.39 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
wavw
wavw Feb. 13 at 9:08 PM
$RANI AWM investments declared 9.9% holding of RANI.
2 · Reply
DragonAlgo
DragonAlgo Feb. 13 at 9:05 AM
🐉 $RANI CALL — DragonAlgo® Signal Contract: RANI CALL Expiry: 2026-03-06 | Strike: $0.50 | Type: CALL Option Plan (premium): Entry: $0.65 Stop: $0.47 TP1: $0.85 TP2: $1.10 TP3: $1.56 🔗 https://dragonalgo.com
0 · Reply
wavw
wavw Feb. 13 at 1:28 AM
$RANI 6.5% acquired by SymBiosis Capital. Recently Vanguard acquired moreover than 5%. Retailers impatiently selling their shares to BIG guys. Sad.
1 · Reply
wavw
wavw Feb. 12 at 3:25 PM
$RANI volume dried up. Need catalyst for investors to get in. The management should look for more deals.
0 · Reply
llchen1204
llchen1204 Feb. 11 at 4:19 PM
$RANI
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 10 at 3:08 PM
$RANI Current Stock Price: $1.32 Contracts to trade: $1.5 RANI Feb 13 2026 Call Entry: $0.14 Exit: $0.23 ROI: 74% Hold ~25 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
wavw
wavw Feb. 10 at 3:06 PM
$RANI 13.5 million shares shorted. They need to cover. Huge spike expected.
0 · Reply
wavw
wavw Feb. 10 at 2:59 PM
$RANI some day traders selling. But sure…someone collecting…see Vanguard. Other players are getting in.
0 · Reply
Tooneyman
Tooneyman Feb. 10 at 2:51 PM
$RANI
0 · Reply
Rkwill
Rkwill Feb. 9 at 10:43 PM
$RANI Tried to buy at $1.25. Guess nobody would sell their shares. The order didn't fill!
1 · Reply